Trials / Completed
CompletedNCT03441568
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
In-home Use Test of the New Modified Diprobase® Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 6 Months – 48 Months
- Healthy volunteers
- Accepted
Summary
To investigate the safety and tolerability of the modified Diprobase formulation over 14 days in infants and children with a history of Atopic Dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Modified Diprobase formulation (BAY987534) | The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face. |
Timeline
- Start date
- 2018-09-26
- Primary completion
- 2019-08-02
- Completion
- 2019-08-02
- First posted
- 2018-02-22
- Last updated
- 2020-07-24
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03441568. Inclusion in this directory is not an endorsement.